Chordia Therapeutics

Chordia Therapeutics is a Japanese clinical-stage biotech company headquartered in Fujisawa, Kanagawa, founded in October 2017 and publicly listed on the Tokyo Stock Exchange (ticker: 190A). The company is engaged in the research and development of next-generation small-molecule anticancer drugs with novel mechanisms of action, focusing on RNA splicing dysregulation and inducing stress overload in cancer cells — a newly proposed hallmark of cancer. Its lead program, Rogocekib (a CLK inhibitor), has advanced into Phase 1 clinical trials for solid tumors, and the company also partners with Takeda and leading academic institutions including Kyoto University and Fujitsu to discover biomarkers and advance its pipeline. Chordia targets cancers with high unmet medical needs using a precision oncology approach grounded in solid scientific evidence.